Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "Elevatum"

    Please enter search terms.

    Enicepatide

    Other names: RG6640; RO7795068; CT-388

    Modality: Biased dual GLP-1/GIP receptor agonist

    Disease State: Type 2 Diabetes, Overweight/Obesity

    Summary

    Enicepatide is an investigational once-weekly subcutaneous injectable, dual glucagon-like peptide-1 and gastric inhibitory polypeptide (GLP-1/GIP) receptor agonist being investigated for the treatment of overweight/obesity and type 2 diabetes (T2D)

    Clinical Trials

    Enicepatide
    NCT ID Study Phase Enrollment Status Study Title
    NCT07351045 Phase III Recruiting A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes View details
    NCT07351058 Phase III Recruiting A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes View details
    NCT06628362 Phase II Active, not recruiting A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus View details

    Proposed Mechanism of Action

    The investigational molecule enicepatide demonstrates biased activity on both the GLP-1 and GIP receptors toward cAMP activation with minimal to no ß-arrestin recruitment on either receptor. This biased signaling is proposed to minimize receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity.3

    Enicepatide is an investigational, Signal-Biased, Dual GLP-1/GIP Receptor Agonist Being Developed for Overweight/Obesity ± T2D and Other Weight-Related Comorbidities4,5

    Enicepatide Mechanism of Action

    Side by side image illustrating unbiased GLP-1RA signalling vs biased receptor modulator and the subsequent limitation of B-arrestin recruitment with retention of cAMP signaling potency1,6

    1. Chakravarthy MV, et al. Presented 59th European Association for the Study of Diabetes Annual Meeting. 2–6 October 2023; Hamburg, Germany. Presentation 75-LB;
    2. Chakravarthy MV, et al. Presented 60th European Association for the Study of Diabetes Annual Meeting. 9–13 September 2024; Madrid, Spain. Presentation LBA 65;
    3. Jones B et al. Nature Communications. 2018;9:160
    4. ClinicalTrials.gov A Study of CT-388 in Participants with Obesity or Overweight with At Least One Weight-Related Comorbidity (CT-388-103) [Internet; cited 2025 February]. Available from: https://clinicaltrials.gov/​study/​NCT06525935?intr=CT-388&rank=1
    5. ClinicalTrials.gov A Study of CT-388 in Participants Who Are Overweight or Obese with Type 2 Diabetes Mellitus (CT-388-104) [Internet; cited 2025 February]. Available from: https://clinicaltrials.gov/​study/​NCT06628362?intr=CT-388&rank=3
    6. Roche Pharma Day 2024 https://assets.roche.com/​f/​176343/​x/​f513f69de2/​pharma_day_20240930_final_online_v02.pdf

    Looking for more information?

    Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

    Connect with an MSL
    Submit a Request

    Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT

    TOP

    • cAMP
      cyclic adenosine monophosphate

    • GLP-1
      Glucagon-like peptide-1

    • GIP
      Glucose-dependent insulinotropic polypeptide

    • GLP1R
      Glucagon-like peptide-1 receptor

    • T2D
      Type 2 Diabetes

    +